We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+2.16%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.73B
AUM Growth
+$336M
Cap. Flow
+$448M
Cap. Flow %
25.88%
Top 10 Hldgs %
59.34%
Holding
67
New
13
Increased
7
Reduced
17
Closed
3

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$166M
2
HRMY icon
Harmony Biosciences
HRMY
+$165M
3
NVAX icon
Novavax
NVAX
+$20M
4
CYTK icon
Cytokinetics
CYTK
+$16.4M
5
MREO
Mereo BioPharma
MREO
+$15.9M

Top Sells

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$7.98M
2
LEGN icon
Legend Biotech
LEGN
+$7.57M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.7M
4
GLMD icon
Galmed Pharmaceuticals
GLMD
+$4.11M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 91.47%
2 Financials 6.31%
3 Materials 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$277M 16.03%
1,797,745
– –
ALXO icon
2
ALX Oncology
ALXO
$268M
$159M 9.2%
+4,220,048
New +$166M
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$154M 8.88%
+4,534,341
New +$165M
NFH
4
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$109M 6.31%
14,300,000
– –
LEGN icon
5
Legend Biotech
LEGN
$3.68B
$103M 5.94%
3,330,269
-224,738
-6% -$7.57M
GTH
6
DELISTED
Genetron Holdings Limited ADS
GTH
$75.7M 4.37%
2,113,287
– –
AMRS
7
DELISTED
Amyris Inc.
AMRS
$38.4M 2.22%
13,158,914
+2,977,442
+29% +$10.9M
SVA
8
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 2.21%
5,900,000
– –
IMVT icon
9
Immunovant
IMVT
$7.99B
$36.7M 2.12%
1,042,460
+242,460
+30% +$7.29M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.88B
$35.5M 2.05%
2,263,770
-52,858
-2% -$808K
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$33.7M 1.94%
5,966,527
– –
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.55B
$32.6M 1.89%
1,113,265
-176,095
-14% -$4.7M
KURA icon
13
Kura Oncology
KURA
$826M
$32.2M 1.86%
1,050,000
– –
ZYME icon
14
Zymeworks
ZYME
$1.66B
$29.8M 1.72%
640,411
-93,750
-13% -$3.22M
PASG icon
15
Passage Bio
PASG
$14.7M
$28.7M 1.66%
109,573
-1,906
-2% -$656K
CLDX icon
16
Celldex Therapeutics
CLDX
$2.79B
$25.5M 1.48%
1,722,500
+122,500
+8% +$1.44M
ARWR icon
17
Arrowhead Research
ARWR
$12.1B
$24.8M 1.43%
576,505
– –
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$21.6M 1.25%
353,511
+10,332
+3% +$524K
MYOK
19
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$21.6M 1.25%
158,310
– –
KDMN
20
DELISTED
Kadmon Holdings, Inc.
KDMN
$20.7M 1.2%
5,291,336
-56,432
-1% -$237K
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$20.5M 1.18%
1,917,074
– –
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$343M
$19.7M 1.14%
860,648
– –
VRNA
23
DELISTED
Verona Pharma
VRNA
$19M 1.1%
3,048,507
+1,555,556
+104% +$10.7M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$18.6M 1.07%
1,476,796
– –
NVAX icon
25
Novavax
NVAX
$1.21B
$17.8M 1.03%
+164,199
New +$20M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Vivo Capital held 67 positions worth $1.73B, up 24% from $1.39B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital deployed $448M of net new capital in Q3 2020, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was ALX Oncology: 4,220,048 shares worth $159M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Legend Biotech, an estimated $7.57M trimmed.

  • Vivo Capital's largest Q3 2020 buy was ALX Oncology: 4,220,048 shares worth $159M.
  • Vivo Capital added most to Mereo BioPharma in Q3 2020, an estimated $15.9M increase.
  • Vivo Capital's biggest Q3 2020 reduction was Legend Biotech, cutting an estimated $7.57M.
  • Vivo Capital fully exited Verastem in Q3 2020, selling an estimated $7.98M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.73B portfolio in Q3 2020.
  • Vivo Capital opened 13 new positions and closed 3 in Q3 2020.
  • Vivo Capital's portfolio value rose 24% quarter-over-quarter to $1.73B.

Based on Vivo Capital's 13F filing for Q3 2020, filed 13 Nov 2020.